# OnCo record eye-care-with-ocular-toxic-antibody-drug-conjugates (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/eye-care-with-ocular-toxic-antibody-drug-conjugates/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "eye-care-with-ocular-toxic-antibody-drug-conjugates" ;
  schema:name "Eye care with antibody-drug conjugates that harm the cornea: belantamab, mirvetuximab, tisotumab and enfortumab"@en ;
  schema:alternateName "ADC eye care"@en, "ADC ocular toxicity"@en, "Blenrep eye exams"@en, "Blenrep REMS"@en, "Elahere eye drops"@en, "Tivdak eye drops and cold packs"@en, "keratopathy with antibody-drug conjugates"@en, "corneal toxicity with ADCs"@en ;
  schema:description "Some antibody-drug conjugates damage the front surface of the eye (the cornea), causing dry, gritty or painful eyes and blurred vision. With belantamab, mirvetuximab and tisotumab, an eye specialist examines you before and during treatment, you use eye drops on a schedule, and no contact lenses. Report any change in your sight at once: the dose can be paused or lowered, and most problems improve."@en ;
  schema:url <https://onco.cc/protocols/eye-care-with-ocular-toxic-antibody-drug-conjugates/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "ocular-toxicity", "antibody-drug-conjugate", "supportive-care" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/drugs/tisotumab-vedotin/>, <https://onco.cc/drugs/enfortumab-vedotin/> ;
  onco:terms <https://onco.cc/terms/ocular-toxicity/>, <https://onco.cc/terms/adc-side-effects-breast/> .